Atherosclerosis is the leading cause of cardiovascular disease (CVD) and the primary determinant of heart disease and stroke, the top two killers worldwide (1) . The high mortality rate associated with atherosclerosis is of particular importance for individuals suffering from familial hypercholesterolemia, a genetic disorder whereby the loss of at least one functional LDL receptor (LDLR) allele results in the inefficient clearance of circulating cholesterol and aggressive atherosclerotic plaque formation resulting in premature CVD (2, 3) . Another genetic determinant that predisposes individuals to CVD is a SNP in the gene encoding the alcohol-metabolizing enzyme aldehyde dehydrogenase 2 (ALDH2). Approximately 40% of East Asians carry this SNP (ALDH2 rs671), which is associated with the phenomenon known as "Asian flush" that occurs with alcohol consumption. While ALDH2 rs671 is associated with an increased risk of atherosclerosis and coronary artery disease (4), it is unknown whether this SNP causally contributes to CVD development.
ALDH2 and atherosclerosis development
In this issue, Zhong et al. provide important mechanistic evidence to address the role of ALDH2 rs671 in CVD (5). The authors employed mouse genetics and deleted Aldh2 in the Ldlr knockout background (Ldlr -/-), a commonly employed experimental model of atherosclerosis, and demonstrated that loss of ALDH2 reduced plaque burden and foam cell formation (fat laden macrophages that contribute to plaque generation and growth). This unexpected observation suggested a critical role for ALDH2 in atherosclerosis pathogenesis. Bone marrow-derived macrophages were identified as the primary cell type responsible for the reduction in plaque load, as transplantation of bone marrow from Aldh2 -/-Ldlr -/-mice into Ldlr -/-mice was sufficient to prevent atherosclerotic plaque formation. As macrophage-mediated clearance of circulating lipids is a key contributor to atherosclerotic progression (6), Zhong and colleagues next interrogated macrophage foam cell formation and the capacity of these cells to metabolize oxidized lipids (uptake, degradation, and efflux). Strikingly, Aldh2
-/-Ldlr -/-macrophages possessed an enhanced lysosomal cholesterol degradation capacity, which correlated with a reduction in foam cell formation. Importantly, Aldh2 deletion alone did not alter lysosomal degradation, indicating that the phenotype was LDLR-dependent. In a carefully designed set of experiments, the authors determined that autolysosome number was substantially increased in Aldh2 -/-Ldlr -/-macrophages, suggesting an enhanced ability to clear lipid-laden endosomes. Notably, this protective effect was abolished when lysosomal pH was neutralized with bafilomycin A1, providing mechanistic links between ALDH2, lysosomal function, and foam cell formation. Collectively, these results suggested the contribution of a pathway that is dependent on ALDH2 and LDLR to the progression of atherosclerosis.
Next, Zhong et al. explored the underlying mechanism by which the interaction of ALDH2 and LDLR regulates foam cell formation and examined ALDH2 enzymatic activity, which was not different between WT and Ldlr -/-mice (5). This result suggested the potential for a direct interaction between the two proteins, and an interaction between LDLR and ALDH2 was experimentally confirmed by co immunoprecipitation. The authors hypothesized that the interaction of LDLR and ALDH2 prevented nuclear translocation, as observed in Ldlr -/-macrophages, and that this may be in part mediated by AMPK phosphorylation. This postulate was supported by previous work showing that AMPK regulates ALDH2 translocation to the nucleus, where it can act as a transcriptional repressor (7 
Conclusions and clinical implications
This serendipitous discovery was further extended toward clinical relevance, as expression of mutant ALDH2 rs671 mimicked the signaling observed with loss of LDLR. Moreover, the ALDH2 SNP prevented the direct interaction with LDLR and allowed for enhanced AMPK interaction and phosphorylation, resulting in ALDH2 rs671 nuclear translocation. This mechanism, in the context of earlier results, provides an explanation for the ALDH2. Of particular interest, Atp6v0e2, a lysosomal proton pump that is required for proper lysosomal function and lipid clearance, was the third most upregulated gene. In a series of elegant molecular studies, Zhong et al. revealed that AMPK phosphorylation of ALDH2 promotes translocation to the nucleus, where its presence suppressed ATP6v0e2 transcription, all of which was prevented when LDLR was available to directly bind and sequester AMPK and ALDH2, preventing phosphorylation of ALDH2 and its nuclear translocation ( Figure 1 ). This finding was important, as it provides a molecular mechanism that accounts for the authors' previous and what is the phosphatase counteracting AMPK phosphorylation. Fourth, what other genes, beyond ATP6V0E2, does ALDH2 regulate and what is the impact on macrophage polarization, inflammation, and secretory factors. Further identification of the genes modulated by ALDH2 nuclear translocation and their impact on the vascular microenvironment could provide additional targets for translational application. Fifth, does a similar mechanism in the regulation of cholesterol metabolism exist outside of the macrophage? Hepatocyte clearance of LDL is the greatest contributor to circulating cholesterol levels. Does this pathway play a role in global lipid metabolism? Sixth, are patients with type 2 diabetes and the ALDH2 SNP who are currently taking metformin at a greater risk of progressive atherosclerosis? Based on the results of Zhong et al., this appears to be an area in need of critical and immediate attention. Finally, what is the functional consequence of this novel ALDH2 signaling pathway in other disease states? Looking beyond atherosclerosis, it is interesting to note that ALDH2 rs671 is also associated with an increased risk of hypertension (9), diabetes mellitus (8), osteoporosis (10), and cancers (11, 12) . Does nuclear translocation of ALDH2 contribute to the pathogenesis of these other disease states?
In summary, the current study by Zhong et al. (5) makes an important mechanistic link regarding the increased prevalence of atherosclerosis in individuals with the ALDH2 rs671 SNP. While the complete underlying mechanisms remain to be elucidated, these findings provide the framework to further delineate the involvement of ALDH2 in not only atherosclerosis, but numerous other disease states of clinical significance.
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prescribed medication for individuals with diabetes, a comorbidity often associated with atherosclerosis. To this point, a recent meta-analysis indicated that the ALDH2 rs671 SNP also correlated with the incidence of type 2 diabetes (8); therefore, prescription of metformin may further increase the risk of atherosclerosis in patients with the ALDH2 rs671 SNP and perhaps this novel signaling pathway is also linked to the pathogenesis of diabetes.
While the study by Zhong et al. provides causative evidence linking ALDH2 to atherosclerosis (5), the exact role of ALDH2 in disease progression remains to be elucidated. There are several questions that have been brought to light by the current study and require further investigation to provide a more holistic view. First, what are the signaling events that lead to AMPK activation during atherosclerosis pathogenesis? As Zhong et al. mention, this appears to not be due to augmentation of conventional regulators (e.g., gene transcription, AMP/ATP levels). A better understanding of the upstream signaling events that lead to AMPK activation and ALDH2 phosphorylation could provide crucial mechanistic insight and novel therapeutic targets for ALDH2 SNP carriers. Second, where does the ALDH2-LDLR-AMPK interaction take place and what determines the subcellular localization of this interaction? Specifically, how do LDLR and AMPK enter the mitochondria to physically interact with ALDH2 and how does this modulate LDLR cycling that occurs with lipid uptake? These fundamental questions need to be addressed to place this novel signaling within the canonical LDLR lipid uptake pathway. Third, how is phosphorylated ALDH2 transported out of the mitochondria and into the nucleus and how is AMPKmediated phosphorylation regulated in the mitochondrial matrix environment? There are limited data to explain how AMPK may function in the mitochondria where the pH is significantly different than the cytosol,
